Last updated: July 16, 2026
Taro Pharmaceuticals USA Inc. v. Glenmark Pharmaceuticals Ltd. (2:18-cv-12569): Litigation Summary, PTAB/Orange Book Posture, and Generic Entry Exposure
Executive summary: The U.S. District Court litigation at 2:18-cv-12569 is part of the Hatch-Waxman Paragraph IV landscape for a branded reference product versus Glenmark generic drug(s), with Taro Pharmaceuticals USA, Inc. as the plaintiff. The docket is the relevant decision source for: (i) whether the case reached a merits judgment versus a stipulated dismissal, (ii) the asserted patents and claims at issue, (iii) the court’s claim-construction and infringement/invalidity rulings (if any), and (iv) any settlement-driven license and “at-risk” launch design.
Actionable point: Without the specific docket entries (complaint filing date, asserted patent numbers, parties’ settlement records, and final judgment orders), a complete and accurate litigation-and-IP posture summary cannot be produced.
What patents were asserted in Taro v. Glenmark 2:18-cv-12569 Paragraph IV case?
Answer (required for an accurate litigation analysis): The asserted U.S. patents and patent claims are not provided in the prompt. A litigation summary that names specific asserted patents, claim numbers, and final holdings depends on the complaint, amended complaint, and the court’s scheduling/claim construction order.
Which active ingredient and reference product was at issue?
The relevant FDA NDA/Orange Book listing (reference listed drug, strength, dosage form) is not provided. Hatch-Waxman case mapping requires the Orange Book listing tied to the “Orange Book patents” asserted in the suit.
What product form and dosage strengths were in play?
Taro v. Glenmark Paragraph IV cases typically attach to a specific dosage form (tablet, capsule, solution, etc.) and one or more strengths. Those specifics are not provided.
How did the court rule on infringement and invalidity in 2:18-cv-12569?
Answer (required for an accurate litigation analysis): The prompt does not include the docket’s dispositive outcomes. A correct summary needs:
- the final judgment entry (or stipulated dismissal with terms),
- any summary judgment orders,
- Daubert evidentiary rulings (if any), and
- any appellate activity (if any).
Did the case reach claim construction?
Without the docket’s Markman order (or minutes), the litigation analysis cannot be completed.
Were there written opinions on §101/§102/§103/§112?
Patent invalidity analysis must reference the court’s reasoning and claim limitations. The prompt provides none.
When did TARO v. GLENMARK 2:18-cv-12569 impact FDA exclusivity timelines?
Answer (required for a complete timeline): Hatch-Waxman litigation timing depends on:
- the ANDA filing date (and whether a 180-day exclusivity claimant triggered a stay),
- the date of complaint (Paragraph IV notice and suit filing), and
- the statutory stay under 21 U.S.C. §355(j)(5)(B)(iii)-(iv).
The prompt does not provide those dates.
Did any 30-month stay expire or get extended by this case?
Stays depend on the court’s milestone decisions. No such milestone dates are present.
Was there an “at-risk” launch before final resolution?
That requires a settlement or court outcome plus ANDA status and launch facts.
What settlement terms or licensing outcomes resolved 2:18-cv-12569?
Answer (required for an accurate litigation analysis): Whether there was a license, consent judgment, dismissal with prejudice, or stipulated dismissal under a settlement cannot be determined without docket entries and/or publicly filed settlement agreements.
Did the parties enter a branded generic supply or license deal?
No settlement documentation is included in the prompt.
Was dismissal with prejudice linked to a launch date?
That is docket-specific and not recoverable from the case caption alone.
Is 2:18-cv-12569 tied to a TRO or preliminary injunction?
Answer (required for an accurate litigation analysis): Preliminary relief would appear as docketed motions (TRO/P.I.) and orders. The prompt provides no order details.
Was there a PI/TRO granted against Glenmark?
No information is provided.
Did the court enforce a design-around or labeling restriction?
No information is provided.
What is the Orange Book status for the relevant Taro reference product patents?
Answer (required for accuracy): Orange Book “patent list” status (expiration date, exclusivity, listings tied to the asserted patents) cannot be stated without knowing the reference product and patent numbers.
Which patents remain listed vs. delisted for the drug at issue?
Cannot be answered without Orange Book data.
Which listed patents were asserted in this case?
Cannot be answered without the complaint.
How strong is the patent estate in the Taro v. Glenmark matter?
Answer (required for an accurate litigation analysis): Patent estate strength requires the full set of:
- asserted patents and their remaining term at suit filing,
- family size, expiration projections, and claim scope,
- any court findings or PTAB outcomes.
None is provided.
What is the remaining life of the asserted patents?
Not provided.
Were there PTAB reviews (IPR/PGR) affecting validity?
No information is provided.
What generic entry risks exist for Glenmark after 2:18-cv-12569?
Answer (required for accuracy): Entry risk depends on:
- whether the case ended in non-infringement/invalidity findings versus settlement,
- whether the dismissal leaves design-around or ongoing claims, and
- whether any remaining patents (not asserted) still block launch.
No case outcome facts are provided.
Does Glenmark retain launch eligibility if only some patents were resolved?
Needs the disposition of each asserted patent.
How do non-asserted patents change “launch at risk” calculus?
Requires the full Orange Book set.
How does Taro’s litigation posture compare with other Paragraph IV cases involving Glenmark?
Answer (required for accuracy): Comparative analysis needs related cases, product, and outcome facts. The prompt provides only one docket caption.
Were there co-defendants or multiple ANDAs asserted in parallel?
Not provided.
Did Glenmark litigate the same reference product in other venues?
Not provided.
Procedural timeline: what happened in 2:18-cv-12569 (filings, motions, orders, and final disposition)?
Answer (required for accuracy): A litigation timeline requires docket events with dates: complaint, responsive pleadings, amended complaint, claim construction schedule, dispositive motions, trial dates, and judgment/dismissal date. The prompt provides none.
Key docket events needed for a defensible litigation summary
- Complaint filed (date) and asserted patents
- Answer and any invalidity/infringement contentions timeline
- Markman/claim construction order (date and holdings)
- Summary judgment/trial outcomes (date and holdings)
- Final judgment or stipulated dismissal (date)
No such data is present.
Key Takeaways
- A credible litigation summary for Taro Pharmaceuticals USA, Inc. v. Glenmark Pharmaceuticals Ltd., 2:18-cv-12569 requires docket-specific facts that are not provided: asserted patent numbers/claims, court rulings, and final disposition (judgment vs. settlement-driven dismissal).
- Without those elements, the analysis cannot be completed to a level suitable for litigation strategy, licensing posture, or regulatory launch risk decisions.
FAQs
- What is the final disposition of Taro v. Glenmark (2:18-cv-12569)?
- Which Orange Book patents were asserted in Taro v. Glenmark (2:18-cv-12569)?
- Did Glenmark receive a 180-day exclusivity-triggering “first filer” position in this matter?
- Were any preliminary injunction or TRO orders entered in 2:18-cv-12569?
- Which patents remain as non-asserted blockers after the case outcome?
References
(No sources can be cited from the provided prompt.)
